Mounjaro, also known as tirzepatide, has shown remarkable effectiveness in promoting weight loss in individuals with and without type 2 diabetes, as indicated by the results of several clinical trials.
Here’s a summary of the weight loss benefits of Mounjaro based on the provided web search results:
Weight Reduction in Clinical Trials:
-
- Participants in a study achieved an average weight loss of 30 pounds or 13.4% of their body weight on the 10 mg dose and 34.4 pounds or 15.7% of their weight on the 15 mg dose, compared with 7 pounds or a 3.3% weight loss with the placebo over 72 weeks.
- In a separate study, individuals with obesity but not diabetes lost an average of 52 pounds (more than 20% of their weight) on the highest dose of tirzepatide .
- The majority of participants in the SURMOUNT-2 trial experienced an average weight reduction of 15.7% at the highest dose, along with other health benefits such as normalized A1C levels, reductions in fasting blood sugars, waist circumference, and body mass index.
Comparison with Other Medications
-
- Mounjaro has been found to offer greater weight loss benefits compared to other type 2 diabetes medications, such as semaglutide (Rybelsus, Ozempic, Wegovy) and long-acting insulins like degludec (Tresiba) and glargine (Lantus) .
FDA Approval for Weight Loss:
-
- In November 2023, the FDA approved tirzepatide for chronic weight management in adults with obesity or overweight with at least one weight-related condition, in addition to a reduced-calorie diet and increased physical activity, under the name Zepbound.
Safety and Side Effects:
-
- Mounjaro/Zepbound can cause side effects such as nausea, diarrhea, vomiting, constipation, abdominal discomfort and pain, injection site reactions, fatigue, hypersensitivity reactions, burping, hair loss, and gastroesophageal reflux disease.
